drugset / Trial / NCT05262101
Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade Sarcoma
Phase 2
Terminated
7 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, open-label, multicenter Phase Ib clinical trial evaluating TQB2858 injection in the treatment of advanced high-grade sarcoma. To evaluate the preliminary efficacy and safety of TQB2858 injection in patients with advanced high-grade sarcoma, and to explore the relevant biomarkers of TQB2858 injection.
Timeline
- Start
- 2022-05-09
- Primary completion
- 2023-06-28
- Completion
- 2023-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB2858 | Protein / enzyme biologic | 1800 mg | Intravenous |